Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

HC Wainwright reissued their buy rating on shares of United Therapeutics (NASDAQ:UTHR – Free Report) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $425.00 ...

United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The stock has a market cap of $14.28 billion, a price-to-earnings ratio of 13.96, a PEG ratio of 0.97 and a beta ...

Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations were $6.1. Operator: Good morning, and welcome to ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. United Therapeutics beat analysts’ revenue ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR – Research Report) and ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on United Therapeutics (UTHR – Research Report), with a ...

United Therapeutics (NASDAQ:UTHR) Corporation reported its fourth-quarter 2024 earnings, revealing a notable miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was 1.2% below analysts’ consensus ...